Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.

Heller DR, Chiuzan C, Taub RN, Leinwand JC, Greene AM, Bates GE, Chabot JA, Kluger MD.

Ann Surg Oncol. 2017 Dec;24(13):3818-3824. doi: 10.1245/s10434-017-6106-x. Epub 2017 Oct 12.

PMID:
29027138
2.

Intimacy, Body Image, and Cancer.

Bates G, Taub RN, West HJ.

JAMA Oncol. 2016 Dec 1;2(12):1667. doi: 10.1001/jamaoncol.2016.1196. No abstract available.

PMID:
27711916
3.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.

PMID:
27621408
4.

Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project.

Bates GE, Hashmi AK, Bressler T, Zajac J, Hesdorffer M, Taub RN.

Transl Lung Cancer Res. 2016 Jun;5(3):216-8. doi: 10.21037/tlcr.2016.05.05.

5.

Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J, Chen K, Testa JR.

Cancer Biol Ther. 2016;17(3):328-35. doi: 10.1080/15384047.2016.1145850. Epub 2016 Feb 6.

6.

Fertility and Cancer Treatment.

Bates GE, Taub RN, West H.

JAMA Oncol. 2016 Feb;2(2):284. doi: 10.1001/jamaoncol.2015.4143. No abstract available.

PMID:
26822339
7.

Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.

Krasinskas AM, Borczuk AC, Hartman DJ, Chabot JA, Taub RN, Mogal A, Pingpank J, Bartlett D, Dacic S.

Histopathology. 2016 Apr;68(5):729-37. doi: 10.1111/his.12807. Epub 2015 Oct 16.

PMID:
26272336
8.

Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.

Domènech-Vilardell A, Rasiej MJ, Taub RN, Ichise M.

Q J Nucl Med Mol Imaging. 2016 Mar;60(1):54-61. Epub 2014 Apr 14.

PMID:
24727854
9.

Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.

Leinwand JC, Zhao B, Guo X, Krishnamoorthy S, Qi J, Graziano JH, Slavkovic VN, Bates GE, Lewin SN, Allendorf JD, Chabot JA, Schwartz LH, Taub RN.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S553-9. doi: 10.1245/s10434-013-2976-8. Epub 2013 May 24.

10.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8. Epub 2013 Mar 2.

11.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.

Lung Cancer. 2012 Sep;77(3):567-71. doi: 10.1016/j.lungcan.2012.05.111. Epub 2012 Jul 4.

PMID:
22770372
12.

Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.

Lagana SM, Taub RN, Borczuk AC.

Arch Pathol Lab Med. 2012 Jul;136(7):804-9. doi: 10.5858/arpa.2011-0219-OA.

PMID:
22742553
13.

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, Taub RN, Matushansky I.

J Clin Invest. 2012 Mar;122(3):886-98. doi: 10.1172/JCI60015. Epub 2012 Feb 1.

14.

Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma.

Matushansky I, Taub RN.

Nat Rev Clin Oncol. 2011 Mar 22;8(7):434-8. doi: 10.1038/nrclinonc.2011.36. Review.

PMID:
21423256
15.

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.

Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA.

Eur J Surg Oncol. 2010 Oct;36(10):997-1003. doi: 10.1016/j.ejso.2010.07.001. Epub 2010 Aug 2.

PMID:
20674253
16.

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma.

Boyar MS, Hesdorffer M, Keohan ML, Jin Z, Taub RN.

Sarcoma. 2008;2008:412503. doi: 10.1155/2008/412503. Epub 2008 Nov 16.

17.

Epithelioid Angiosarcoma of the Small Intestine After Occupational Exposure to Radiation and Polyvinyl Chloride: A case Report and Review of Literature.

Khalil MF, Thomas A, Aassad A, Rubin M, Taub RN.

Sarcoma. 2005;9(3-4):161-4. doi: 10.1080/13577140500389069.

18.

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.

Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN.

Am J Clin Oncol. 2008 Feb;31(1):49-54. doi: 10.1097/COC.0b013e3180684181.

PMID:
18376228
19.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.

PMID:
18349397
20.

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC.

Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.

21.

New strategies for treating GIST when imatinib fails.

Boyar MS, Taub RN.

Cancer Invest. 2007 Aug;25(5):328-35.

PMID:
17661208
22.

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.

Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA.

Oncogene. 2007 Jan 25;26(4):610-7. Epub 2006 Jul 24.

PMID:
16862182
23.

Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.

Saqi A, Yun SS, Yu GH, Alexis D, Taub RN, Powell CA, Borczuk AC.

Diagn Cytopathol. 2005 Aug;33(2):65-70.

PMID:
16007640
24.

P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma.

Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML, Alsberry R, Alexis D, Powell CA.

Clin Cancer Res. 2005 May 1;11(9):3303-8.

25.

The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D.

Cancer Immun. 2004 Aug 9;4:7.

26.

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.

Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, Taub RN.

Cancer. 2003 Nov 1;98(9):1942-6.

27.

SSX antigens as tumor vaccine targets in human sarcoma.

Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D.

Cancer Immun. 2003 Oct 9;3:13.

28.

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

Talbot SM, Rankin C, Taub RN, Balcerzak SP Jr, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.

Cancer. 2003 Jul 15;98(2):331-6.

29.

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.

Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ, Bar M, del Prete S, March R, Lonberg M, Talbot S, Mears JG, Flamm M, Taub RN, Nichols G.

Leuk Lymphoma. 2003 Mar;44(3):477-81.

PMID:
12688318
30.

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P, Cerottini JC, Hesdorffer CS, Old LJ, Valmori D.

J Clin Invest. 2002 Dec;110(12):1813-22.

31.

Combined heart and lung transplantation for unresectable primary cardiac sarcoma.

Talbot SM, Taub RN, Keohan ML, Edwards N, Galantowicz ME, Schulman LL.

J Thorac Cardiovasc Surg. 2002 Dec;124(6):1145-8.

32.

Peritoneal mesothelioma.

Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M.

Curr Treat Options Oncol. 2000 Oct;1(4):303-12. Review.

PMID:
12057156
33.

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K.

J Clin Oncol. 2002 Jan 1;20(1):274-81.

PMID:
11773179
34.

Chemotherapy for malignant mesothelioma.

Taub RN, Antman KH.

Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):361-6. Review.

PMID:
9352953
35.

Chemotherapy for advanced sarcoma: therapeutic decisions and modalities.

Keohan ML, Taub RN.

Semin Oncol. 1997 Oct;24(5):572-9. Review.

PMID:
9344324
36.

Homogeneously staining region in anthracycline-resistant HL-60/AR cells not associated with MDR1 amplification.

Gervasoni JE Jr, Taub RN, Yu MT, Warburton D, Sabbath M, Gilleran S, Coppock DL, D'Alessandri J, Krishna S, Rosado M, et al.

Cancer Res. 1992 Oct 1;52(19):5244-9.

37.

Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.

Gervasoni JE Jr, Fields SZ, Krishna S, Baker MA, Rosado M, Thuraisamy K, Hindenburg AA, Taub RN.

Cancer Res. 1991 Sep 15;51(18):4955-63.

38.

Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.

Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K, Ross DD, Baker MA, Lutzky J, et al.

Cancer Chemother Pharmacol. 1991;28(2):93-101.

PMID:
1711935
39.

Human leukemic myeloblasts and myeloblastoid cells contain the enzyme cytidine 5'-monophosphate-N-acetylneuraminic acid:Gal beta 1-3GalNAc alpha (2-3)-sialyltransferase.

Kanani A, Sutherland DR, Fibach E, Matta KL, Hindenburg A, Brockhausen I, Kuhns W, Taub RN, van den Eijnden DH, Baker MA.

Cancer Res. 1990 Aug 15;50(16):5003-7.

40.
41.

Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

Hindenburg AA, Gervasoni JE Jr, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN.

Cancer Res. 1989 Aug 15;49(16):4607-14.

42.

Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.

Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE Jr, Rosado M, Stewart V, Krishna S, Hindenburg AA.

Cancer Res. 1989 Aug 1;49(15):4120-5.

44.

Treatment of anthracycline extravasation--a warning against the use of sodium bicarbonate.

Kappel B, Hindenburg AA, Taub RN.

J Clin Oncol. 1987 May;5(5):825-6. No abstract available.

PMID:
3471867
45.

Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.

Hindenburg AA, Baker MA, Gleyzer E, Stewart VJ, Case N, Taub RN.

Cancer Res. 1987 Mar 1;47(5):1421-5.

46.

Changes in the granulocyte membrane following chemotherapy for chronic myelogenous leukaemia.

Baker MA, Kanani A, Hindenburg A, Taub RN.

Br J Haematol. 1986 Mar;62(3):431-8.

PMID:
3456789
47.

Increased activity of a specific sialyltransferase in chronic myelogenous leukemia.

Baker MA, Taub RN, Kanani A, Brockhausen I, Hindenburg A.

Blood. 1985 Nov;66(5):1068-71.

48.

Isolation and characterization of an anthracycline-resistant human leukemic cell line.

Bhalla K, Hindenburg A, Taub RN, Grant S.

Cancer Res. 1985 Aug;45(8):3657-62.

49.

Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.

Hindenburg AA, Taub RN, Grant S, Chang G, Baker MA.

Cancer Res. 1985 Jul;45(7):3048-52.

50.

Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes.

Taub RN, Hindenburg AA, Baker MA.

Leuk Res. 1985;9(4):507-10.

PMID:
3858613

Supplemental Content

Support Center